Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer By Ogkologos - November 18, 2024 603 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Studies Assess Impact of Cancer Risk-Reduction Measures for People with BRCA... April 15, 2024 Erdafitinib Prolongs Survival in Patients with Metastatic Urothelial Carcinoma and FGFR... November 3, 2023 EMA Recommends Extension of Indications for Lorlatinib December 20, 2021 During No-Visitor Policy at Hospital, Surgeon Comforts Breast Cancer Patient Getting... April 14, 2020 Load more HOT NEWS Mother Spent 14 Weeks Battling Breast Cancer Alone During COVID-19 Lockdown Increase in Node-Positive and Stage III Breast Cancer After Two Months... EMA Recommends Extension of Indications for Niraparib Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic...
